BUZZ-与第一三共合作开发抗癌药物，Tempus AI 股价上涨

路透中文

Mar 25

BUZZ-与第一三共合作开发抗癌药物，<a href="https://laohu8.com/S/TEM">Tempus AI</a> 股价上涨

3月25日 - ** 基因测试公司Tempus AI TEM.O股价盘前上涨2%至49.34美元

** 该公司称，它与日本第一三共公司合作，利用人工智能快速开发治疗癌症的药物

** 交易的核心是一种抗体药物偶联物，这是一种能将化疗直接作用于肿瘤细胞的靶向治疗方法

** Tempus表示，它将利用人工智能工具和大量真实世界的患者数据来寻找生物标志物--显示哪些患者可能受益的生物信号

** 补充说，两家公司将联合建立人工智能模型，为试验挑选患者，并更好地了解不同患者对药物的反应。

** 未披露合作的财务条款

** 2025 年 TEM 股价上涨约 75%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2622076512"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622076512\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622076512?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-25 20:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622076512","market":"us","top_or_hot":-1,"title":"BUZZ-与第一三共合作开发抗癌药物，Tempus AI 股价上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-与第一三共合作开发抗癌药物，<a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> 股价上涨</title></head><body><p><span>3月25日</span><span> - </span>** 基因测试公司Tempus AI <span>TEM.O</span>股价盘前上涨2%至49.34美元</p><p>** 该公司称，它与日本第一三共公司合作，利用人工智能快速开发治疗癌症的药物</p><p>** 交易的核心是一种抗体药物偶联物，这是一种能将化疗直接作用于肿瘤细胞的靶向治疗方法</p><p>** Tempus表示，它将利用人工智能工具和大量真实世界的患者数据来寻找<a href=\"https://laohu8.com/S/000504\">生物</a>标志物--显示哪些患者可能受益的生物信号 </p><p>** 补充说，两家公司将联合建立人工智能模型，为试验挑选患者，并更好地了解不同患者对药物的反应。 </p><p>** 未披露合作的财务条款 </p><p>** 2025 年 TEM 股价上涨约 75%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-与第一三共合作开发抗癌药物，Tempus AI 股价上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-与第一三共合作开发抗癌药物，Tempus AI 股价上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-03-25 20:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-与第一三共合作开发抗癌药物，<a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> 股价上涨</title></head><body><p><span>3月25日</span><span> - </span>** 基因测试公司Tempus AI <span>TEM.O</span>股价盘前上涨2%至49.34美元</p><p>** 该公司称，它与日本第一三共公司合作，利用人工智能快速开发治疗癌症的药物</p><p>** 交易的核心是一种抗体药物偶联物，这是一种能将化疗直接作用于肿瘤细胞的靶向治疗方法</p><p>** Tempus表示，它将利用人工智能工具和大量真实世界的患者数据来寻找<a href=\"https://laohu8.com/S/000504\">生物</a>标志物--显示哪些患者可能受益的生物信号 </p><p>** 补充说，两家公司将联合建立人工智能模型，为试验挑选患者，并更好地了解不同患者对药物的反应。 </p><p>** 未披露合作的财务条款 </p><p>** 2025 年 TEM 股价上涨约 75%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4611","symbol_name":"AI医疗","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4T40D16A:1","article_id":"2622076512","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622076512","pubTimestamp":1774442953,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4611":"AI医疗","BK4121":"生命科学工具和服务","TEM":"Tempus AI","TEMT":"2倍做多TEM ETF-Tradr","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4613":"AI应用软件","LU1861558580.USD":"日兴方舟颠覆性创新基金B"},"translate_title":"BUZZ-Tempus AI shares rise after partnership with Daiichi Sankyo on cancer drug","themeId":"37684715aaf54a73b9fe52ee56a263cc","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEMT":0.6,"TEM":1.96},"content_text":"BUZZ-与第一三共合作开发抗癌药物，Tempus AI 股价上涨3月25日 - ** 基因测试公司Tempus AI TEM.O股价盘前上涨2%至49.34美元** 该公司称，它与日本第一三共公司合作，利用人工智能快速开发治疗癌症的药物** 交易的核心是一种抗体药物偶联物，这是一种能将化疗直接作用于肿瘤细胞的靶向治疗方法** Tempus表示，它将利用人工智能工具和大量真实世界的患者数据来寻找生物标志物--显示哪些患者可能受益的生物信号 ** 补充说，两家公司将联合建立人工智能模型，为试验挑选患者，并更好地了解不同患者对药物的反应。 ** 未披露合作的财务条款 ** 2025 年 TEM 股价上涨约 75%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}